Multiple Myeloma Clinical Trial
— MINIALO-VELCADOfficial title:
MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
Verified date | October 2014 |
Source | PETHEMA Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
The primary objective of this study is to analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib in the treatment of multiple myeloma with bad prognosis, in order to evaluate the response and relapse rates
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 66 Years |
Eligibility |
Inclusion Criteria: - Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements. - Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. - Age over 18 and under 67 years old. - Patient diagnosed with symptomatic Multiple Myeloma based on standard criteria with bad prognosis. This factor is associated with at least one of the clinical alterations defined as follows: Patient who displayed a Monosomy of chromosome 13 or other adverse cytogenetic abnormality. Patient in first relapse. Patient with relapsed multiple myeloma after autologous transplantation. - Patient has a ECOG performance status <= 2. - Patient has a life-expectancy >3 months. - Patients who are candidates for autologous transplantation. - Patients must have HLA-identical sibling donors. - Patient has the following laboratory values before Baseline visit: Platelet count = 30000/mm3 (transfusion allowed), hemoglobin = 8 g/dl (transfusion allowed) and absolute neutrophil count (ANC) = 0.750/mm3. Lower values are accepted if they are caused by bone marrow infiltration. Aspartate transaminase (AST): = 2.5 x the upper limit of normal. Alanine transaminase (ALT): ): = 2.5 x the upper limit of normal. Total bilirubin: =1.5 x the upper limit of normal. Serum creatinine value = 2mg/dl Exclusion Criteria: - Patient present serious pathologies that make impossible chemotherapy treatments: 1. Congestive heart failure, angina or heart attack during last 12 months. 2. Uncontrolled arterial hypertension. 3. Uncontrolled supraventricular arrhythmias during last 3 last months. 4. Ventricular arrhythmia. 5. Hepatic disease (Cirrhosis). - Patient has Grade 2 peripheral neuropathy within 14 days before enrollment. - Patient with serious psychiatric disorders that make impossible comply satisfactorily with the protocol requirements. - Personal medical history of neoplasia of other type, except: carcinoma in situ, other curatively treated malignancy in complete remission for more than 10 years. - Patient has hypersensitivity to bortezomib, boron or mannitol. - Fertile patient is not going to use a medical effective contraceptive method during the trial. - Patient has received other investigational drugs within 30 days before enrollment - Patient is known to be seropositive for the human immunodeficiency virus (HIV), Hepatitis B surface antigen-positive or active hepatitis C infection. - Patient had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. - Patient is enrolled in another clinical research study and/or is receiving an investigational agent for any reason. - Patient participated in clinical study VISTA. - Pregnant or breast-feeding women. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | H. Clinic I Provincial | Barcelona | |
Spain | H. de la Santa Creu I Sant Pau | Barcelona | |
Spain | Instituto Catalán de Oncología | Barcelona | |
Spain | H. de Jerez | Jerez de la Frontera | |
Spain | H. 12 de Octubre | Madrid | |
Spain | H. Univ. Gregorio Marañón | Madrid | |
Spain | H. Univ. La Princesa | Madrid | |
Spain | H. Univ. Morales Meseguer | Murcia | |
Spain | H. Univ. Son Dureta | Palma de Mallorca | |
Spain | H. Univ. de Salamanca | Salamanca |
Lead Sponsor | Collaborator |
---|---|
PETHEMA Foundation |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib | 2 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |